Company profile
VISTAGEN THERAPEUTICS, INC.
NASDAQ:VTGNBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| AV-101 | phase2 | — | 4 | completed, unknown |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06809179 | phase2 | recruiting | 2025-01-09 | 2026-04-01 | VistaGen Therapeutics, Inc. | A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder |
| NCT04147949 | phase2 | unknown | 2022-08-01 | 2023-12-01 | VistaGen Therapeutics, Inc. | AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia |
| NCT05280054 | phase1 | unknown | 2021-12-23 | 2022-09-01 | VistaGen Therapeutics, Inc. | AV-101 Alone and in Combination With Probenecid in Healthy Subjects |
| NCT03078322 | phase2 | completed | 2018-03-05 | 2019-10-01 | VistaGen Therapeutics, Inc. | AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression |
| NCT06358651 | phase3 | active_not_recruiting | 2024-03-28 | 2025-10-31 | VistaGen Therapeutics, Inc. | Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3) |
FDA applications (0)
No records yet.